Secukinumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Giant Cell Arteritis
Conditions
Giant Cell Arteritis, Polymyalgia Rheumatica
Trial Timeline
Mar 27, 2024 → Apr 2, 2025
NCT ID
NCT06130540About Secukinumab
Secukinumab is a phase 1 stage product being developed by Novartis for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT06130540. Target conditions include Giant Cell Arteritis, Polymyalgia Rheumatica.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05583604 | Pre-clinical | Active |
| NCT07243782 | Pre-clinical | Recruiting |
| NCT06751238 | Phase 1 | Recruiting |
| NCT06905288 | Pre-clinical | Recruiting |
| NCT06331312 | Phase 3 | Recruiting |
| NCT06130540 | Phase 1 | Completed |
| NCT05569174 | Phase 3 | Completed |
| NCT05232864 | Phase 3 | Terminated |
| NCT05206591 | Phase 3 | Withdrawn |
| NCT04894890 | Pre-clinical | Completed |
| NCT04717466 | Approved | Completed |
| NCT05677542 | Pre-clinical | Completed |
| NCT05513014 | Pre-clinical | Completed |
| NCT05320159 | Pre-clinical | Completed |
| NCT05650060 | Pre-clinical | Completed |
| NCT03866317 | Phase 2 | Withdrawn |
| NCT03769168 | Phase 3 | Completed |
| NCT03791060 | Phase 2 | Terminated |
| NCT03440736 | Approved | Completed |
| NCT03307447 | Approved | UNKNOWN |
Competing Products
20 competing products in Giant Cell Arteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| prednisone | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Pexidartinib | Daiichi Sankyo | Phase 2 | 52 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 77 |
| Pexidartinib | Daiichi Sankyo | Approved | 85 |
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| Upadacitinib + Corticosteroid (CS) | AbbVie | Phase 3 | 77 |
| dovitinib | Novartis | Phase 2 | 52 |
| Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. | Novartis | Phase 3 | 77 |
| Secukinumab 300 mg, s.c. + Prednisolone + Placebo | Novartis | Phase 2 | 52 |
| Secukinumab 300 mg + Secukinumab 150 mg | Novartis | Phase 3 | 77 |
| Tocilizumab + Placebo | Roche | Phase 3 | 77 |
| Tocilizumab + Prednisone | Roche | Approved | 85 |
| Tocilizumab | Roche | Phase 3 | 77 |
| Tocilizumab | Roche | Phase 1 | 33 |
| Valganciclovir | Roche | Approved | 85 |
| Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate | Roche | Phase 3 | 77 |
| Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs) | Roche | Phase 2 | 52 |
| tocilizumab and IV steroids combination | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Approved | 84 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Amgen | Phase 2 | 51 |